• Ophthalmology

    In the area of ophthalmology, Paradigm has planned and executed a number of recent CME/CE activities focused on the prevention and management of diabetic retinopathy and related eye disorders, including new and emerging breakthroughs and where they fit within the changing treatment paradigm.

    To view all our web activities regarding ophthalmology please click here.

DIAGNOSIS AND TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION: EARLIER IS BETTER

In "Diagnosis and Treatment of Myopic Choroidal Neovascularization: Earlier Is Better," a 1-hour interactive audio webinar for comprehensive ophthalmologists and optometrists, the expert faculty of Sunir J. Garg, MD, and Mark T. Dunbar, OD, reviews the pathology and symptoms of mCNV; makes evidence-based diagnostic recommendations for detecting disease as early as possible; compares distinguishing features of anti-VEGF agents commonly used to treat mCNV, including ease of administration, available formulations, and cost-effectiveness; and evaluates recently reported data on the safety, efficacy, and treatment durability of anti-VEGF agents for treating mCNV. The program's educational objectives are augmented by 1) video demonstration of intraocular injection of anti-VEGF agents and 2) presentation of interactive case studies of myopic choroidal neovascularization.

 

UPDATES ON THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION: EARLIER INTERVENTION IS BETTER

Eye care specialists frequently cite challenges in providing prompt, accurate diagnosis and early treatment as obstacles to providing optimal care for patients with (mCNV). In particular, challenges relating to the differential diagnosis of mCNV must be overcome so that treatment can be initiated early enough to avoid permanent vision loss.

Anti-vascular endothelial growth factor (VEGF) therapies are recommended as first-line for treatment of this condition; however, retina specialists and comprehensive ophthalmologists might not be up-to-date on clinical trial data relating to the efficacy, safety, cost-effectiveness, and convenience of use of various anti-VEGF agents. The proposed educational activity will provide a case-enhanced, expert-led review of evidence-based treatment of mCNV to help physicians with the optimal management of this condition.

 

CLARIFYING THE ROLE OF NOVEL AND EMERGING TREATMENTS FOR DIABETIC RETINOPATHY AND RELATED EYE DISORDERS

This live, interactive, CME-certified symposium will be held at the AAO 2015 Annual Meeting, November 14-17, 2015 and will incorporate didactic lectures, interactive patient case studies, videos of injection techniques, and in-depth moderated Q&A between attendees and faculty. Throughout the symposium, attendees will use iPads, provided by Educational Measures, to view the program, take notes, and interact with faculty. An enduring, text-based, interactive web monograph, including links to relevant audio and video from the live ancillary symposium, will be hosted on the Paradigm website, www.paradigmmc.com, and distributed via Paradigm as well as Healio's Ophthalmology Education Lab website, www.healio.com/ophthalmology, online home of Ophthalmic Surgery, Lasers and Imaging and Retina and Ocular Surgery News.

This activity expired for credit on January 29, 2017

 

DIABETIC RETINOPATHY AND RELATED EYE DISORDERS: NEW DEVELOPMENTS IN DIAGNOSIS AND TREATMENT

This text-based, case-enhanced, interactive, CME-certified web monograph includes links to relevant audio clips derived from a recorded faculty teleconference. It is hosted on the Paradigm website, www.paradigmmc.com and is also being distributed via Healio's Ophthalmology and Optometry websites, www.healio.com/ophthalmology, online home of Ophthalmic Surgery, Lasers and Imaging, Retina and Ocular Surgery News, and www.healio.com/optometry.

This activity expired for credit on September 4, 2016

 

PREVENTION AND MANAGEMENT OF DIABETIC RETINOPATHY AND RELATED EYE DISORDERS: CLARIFYING THE ENDOCRINOLOGIST'S ROLE

Diabetic retinopathy (DR) is a common microvascular complication of diabetes and the leading cause of blindness among working-age adults. Recent treatment advances that target vascular endothelial growth factor and inflammation have allowed patients with DR to stabilize vision - and, in many cases, regain some of their lost vision. Unfortunately, many patients with diabetes fail to receive recommended eye care that would allow for detection and treatment of DR early enough to optimize outcomes among patients with this disease, which is progressive without treatment. This educational activity will increase awareness of the widespread problem of low adherence to recommended diabetic eye care, the importance of suspecting diabetic eye problems (and referring to/partnering with eye care specialists), and the potential of newer agents to improve visual acuity. The critical importance of regular eye screenings to detect early retinal damage, which is typically asymptomatic, will be underscored.

This activity expired for credit on September 1, 2016

 

INDIVIDUALIZED TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA: A CASE-BASED GUIDE TO APPLYING NEW DATA

This series of 3 Case Consults™ CME Web Activities offers a serial learning design consisting of 3 digitally-delivered quarter-hour case activities designed to enhance clinical skill development of retina specialists managing DR and DME. Using the RealCME platform, each activity will utilize text, faculty audio clips, dynamic tools for interdisciplinary communication, and instructional intravitreal injection videos to guide learners through interactive patient case studies, where they will be required to respond to questions at critical decision points in the course of treatment. This web initiative will be distributed by Paradigm and PeerAudience's OpenCME Network.

Case Scenario 1: Proliferative Diabetic Retinopathy and Diabetic Macular Edema

Case Scenario 2: Diabetic Macular Edema

Case Scenario 3: Refractory Diabetic Macular Edema

This activity expired for credit on October 30, 2016